Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 7/20 | 0.65 |
| ▸ | FDPS | P14324 | 12/20 | 0.63 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.61 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.61 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.61 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19961999 | 1.00 | GGPS1 (0.65) | GGPS1FDPSSMPD1LPAR3LPAR1 | |
| SCHEMBL19840566 | 1.00 | GGPS1 (0.65) | GGPS1FDPSSMPD1LPAR3LPAR1 | |
| SCHEMBL3980053 | 0.98 | GGPS1 (0.63) | GGPS1FDPSSMPD1LPAR3LPAR1 | |
| SCHEMBL27574135 | 0.98 | GGPS1 (0.63) | GGPS1FDPSSMPD1LPAR3LPAR1 | |
| SCHEMBL10951449 | 0.91 | GGPS1 (0.61) | GGPS1FDPSSMPD1LPAR3LPAR1 | |
| SCHEMBL3980154 | 0.91 | GGPS1 (0.61) | GGPS1FDPSSMPD1LPAR3LPAR1 | |
| SCHEMBL3890040 | 0.91 | FDPS (0.58) | GGPS1FDPSSMPD1LPAR3LPAR1 | |
| SCHEMBL24067441 | 0.83 | FDPS (0.57) | GGPS1FDPSSMPD1LPAR3LPAR1 | |
| SCHEMBL24067506 | 0.83 | FDPS (0.57) | GGPS1FDPSSMPD1LPAR3LPAR1 | |
| SCHEMBL18575644 | 0.82 | FDPS (0.54) | GGPS1FDPSSMPD1LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | GGPS1 593/4885FDPS 2964/4885SMPD1 52/4885 |
| US-20210369747-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | GGPS1 593/4885FDPS 2964/4885SMPD1 52/4885 |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ENPP1, STING1, ENPP3 | GGPS1 131/4885FDPS 1368/4885SMPD1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.